1 Cell Free Expression Market Size, Share Trends, Forecasts (2035)

Cell Free Expression Market

Cell Free System Market

  • Lowest Price Guaranteed From USD 5,899

  • Published
    June 2023

  • Pages
    192

  • View Count
    315

Cell Free System Overview

The global cell free expression market is estimated to be USD 275 million in 2023 and is anticipated to grow at a CAGR of 7.5% till 2035. In recent years, cell free systems / cell free expression systems have emerged as a promising alternative for the conventional cell based biomanufacturing process. It is a well-known fact that traditional biomanufacturing is a complex process that requires living cells and specific conditions in order to maintain proper homeostasis for cell growth. Moreover, cell based biomanufacturing imposes inherent limitations on the effective production of biologics. On the other hand, cell free system / cell free expression system are ¬in-vitro platforms that harness the transcription and translation machinery of living cells, in the form of cell lysates, to synthesize various types of biologics, particularly proteins.

Overall, cell free system offers several advantages over the traditional process, including the ability to produce a broad range of target molecules by altering components suited for their production, higher yield, shorter development times and low cost of production. Cell free expression is carried out using cell free system or commercially available cell free expression kits. Cell-free protein expression systems have demonstrated to be capable of enabling the synthesis of several complex proteins, including toxic proteins, membrane proteins and other post translationally modified proteins, which have been found to be challenging to express using cell based systems. Given the growing demand for biologic products, cell free expression has become a key focus area for stakeholders in the biopharmaceutical industry. Further, we have considered the ongoing activity and existing trends in the cell free system market to anticipate the global cell free expression market. The market is expected to witness healthy growth during the forecast period.

Key Market Insights

The Cell Free System Market: Cell free Expression Kits and  Service Providers - Distribution by Type of Cell Free System (Crude Cell Lysate-Based Systems and Reconstituted Systems), Type of Host Organism (Microbial Cell Free Expression System, Mammalian Cell Free Expression System, Plant-based Cell Free Expression System and Other Cell Free Expression Systems), Type of Expression Method (Coupled Transcription and Translation Method and Translation Method), End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes and Other End-Users) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive market research of the current market landscape of cell free expression kits and contract manufacturers / research organizations offering cell free expression service, cell free expression market size  and likely future potential associated with the industry, during the forecast period. The report answers many key questions related to this market.

Need for Cell Free Expression / Cell Free Biomanufacturing

Driven by several blockbuster products and a burgeoning pipeline, biologics (and consequently their manufacturing) have emerged as one of the key focus areas for stakeholders engaged in the pharmaceutical industry. However, biologic manufacturing is often fraught with several challenges, including inconsistencies related to quality of the final product, facility limitations, high attrition rate of pipeline candidates, prolonged development timelines, and regulatory / compliance-related issues. Therefore, biopharmaceutical firms are actively taking initiatives to identify approaches to overcome the existing challenges associated with biologic manufacturing. Amongst several alternatives, the use of various types of cell free expression systems, including microbial cell free expression systems, mammalian cell free expression systems, plant-based cell free expression systems and other cell free expression systems, has emerged as a viable option for the synthesis of biotherapeutics. This can be attributed to the fact that cell free expression systems enable faster and economical synthesis of complex molecules in shorter time.

Key Advantages of Cell Free System

Cell free system allows consistent manufacturing of products at varying scales of production (from very small (microliter) to very large (1000 L)), by using the same stockpile of reagents. Additionally, the absence of cell walls in cell free system helps in optimizing various steps of the overall biomanufacturing process by facilitating the addition / removal of enzymes and cofactors (which are continuously produced and degraded at varying rates by living cells), as well as enabling direct monitoring of the entire process. Further, cell free expression systems allow rapid manufacturing of time-sensitive products (such as the required therapies / vaccines during a pandemic) from the previously harvested active ribosomes and other necessary cellular machinery.

Cell Free System Market Landscape

There are companies offering cell free expression kits or cell free expression services. The service providers landscape is fragmented, featuring a mix of several large, mid-sized and small companies. It is worth mentioning that, currently, more than 35 players across the world offer a range of cell free expression services. Majority of these players are based in the US, followed by those having headquarters in Europe and Asia Pacific. Further, over 90 cell free expression kits are presently available in the market for cell free expression of proteins, oligonucleotides and other biomolecules. Interestingly, most of these kits are used for cell-free protein expression. Given the inclination towards cutting-edge technologies, along with innovative approaches to tailor the cell free synthesis, we believe that the cell free expression market is likely to evolve at a rapid pace, during the forecast period 2023-2035.

This image highlights market landscape of cell free expression systems. Presently, more than 35 players across the globe claim to offer cell free expression services for synthesis of a variety of biomolecules

Cell-Free Protein Expression is Driving the Partnership Activity in the Overall Market

Several stakeholders have been forging alliances with other industry / non-industry players in cell free expression market for product development, research and development and technology licensing purposes. It is worth highlighting that, since 2018, over 40 strategic partnerships have been inked in the industry. Majority of these agreements were signed for cell-free protein expression of complex proteins, including toxic proteins, membrane proteins and other post translationally modified proteins.

This image provides details on various partnerships forged between the companies for cell free systems. The growing interest is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to cell free systems were inked in 2022

Owing to several advantages of cell free system, the stakeholders are also acquiring other industry players specializing in various aspects of cell free expression / biomanufacturing in order to expand their capabilities and build a comprehensive product / service portfolio. In January 2023, Moderna acquired OriCiro Genomics, a pioneer in cell free DNA synthesis and amplification technologies, to obtain best-in-class tools for cell free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing. 

 

Cell Free System Also Support Manufacturing of Enzymes and Oligonucleotides

Cell free expression system has emerged as potent technology in the field of synthetic biology for high-throughput production of proteins as well as enzymes and oligonucleotides (DNA/RNA). It is worth highlighting that Enzymit, a bioproduction firm, utilizes cell free technology to synthesize cost-effective enzymes. Further, Touchlight, a UK based company, claims to manufacture its proprietary dbDNA™ at exceptional speed and large scales using cell free synthesis process. The company claims to use its dbDNA™, as a critical synthesis material for development of DNA and mRNA vaccines and cell and gene therapies.

Cell Free Expression Market Size

Owing to the several advantages offered by cell free synthesis over the traditional cell-based manufacturing process, the global cell free expression market is anticipated to grow at an annualized rate (CAGR) of 7.5% during the forecast period 2023-2035. It is worth highlighting that, in terms of type of cell free expression system, the microbial cell free expression system is expected to capture the majority share in the cell free expression market by 2035. Further, amongst the key geographical regions, North America is anticipated to represent the highest share of the cell free expression market in 2035.

This image provides details on cell free systems market size. The cell free expression market is likely to grow at a CAGR of 7.5%, till 2035; this opportunity is expected to be well distributed across different types of cell free systems, host organisms and expression methods

Leading Companies in Cell Free Expression Market

Examples of companies providing cell free synthesis and other associated services include (which have also been captured in this report) BioLinker, CUSABIO, LenioBio and Touchlight. Additionally, examples of players engaged in the development of cell free expression kits include (which have also been captured in this report) biotechrabbit, CellFree Sciences, Creative Biolabs, Daicel Arbor Biosciences, Promega and Thermo Fisher Scientific.

Scope of the Report

The market research presents an in-depth analysis of the various firms / organizations that are engaged in this industry, across different segments (as defined in the table below).

Key Report Attributes Details

Forecast Period

2023-2035

Base Year

2022

Market Size 2023

$275 million

CAGR

7.5%

Type of Cell Free System

Crude cell lysate based systems
Reconstituted systems

Type of Host Organism

Microbial cell free expresion systems
Mammalian cell free expression systems
Plant-based cell free expression system
Other cell free expression systems 

Type of Expression Method

Coupled transcription and translation method
Translation method
End User Pharmaceutical and biotechnology companies
Academic and research institutes
Other end-users
Key Geographical Regions

North America
Europe
Asia-Pacific
Rest of the World

Example Companies Profiled

BioLinker
biotechrabbit
CellFreeSciences
Creative Biolabs
CUSABIO
Daicel Arbor Biosciences
LenioBio
Promega
Thermo Fisher Scientific
Touchlight

Customizatiion Scope 15% Free Customization Option (equivalent to 5 analyst working days)
PowerpPoint Presentation (Complimentary)  Available
Excel Data Packs Market Landscape Analysis
Company Competitiveness Analysis
Product Competitiveness Analysis
Partnerships and Collaborations Analysis
Funding and Investment Analysis
Patent Analysis
Market Forecast an Opportunity Analysis

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different regions. Amongst other elements, the research report includes:

  • An executive summary of insights captured during our research. It offers a high-level view on the current state of the cell free expression market and its likely evolution in the given forecast period.
  • A general overview of cell free systems, the different types of such systems and their composition. It provides a brief outline of the cell free expression process, highlighting several challenges and advantages associated with this technique. It also features applications of cell free expression in the healthcare industry, as well as other industries and a discussion on future prospects of cell free expression. 
  • A detailed assessment of the current market landscape of cell free expression service providers, based on several relevant parameters, such as year of establishment, company size (in terms of employee count), location of headquarters, type of cell free  service(s) offered (biomolecule synthesis / expression, template construction, scaled-up production, process optimization and feasibility testing), type of associated service(s) offered (purification, quality control and others), type of host organism (E. coli, wheat germ, HeLa / human cell lysate, rabbit reticulosyte, Nicotiana tabacum, Spodoptera frugiperda, Chinese hamster ovary, rice cell system, Saccharomyces cerevisiae  and silkworm), type of product(s) synthesized (membrane proteins, toxic proteins, proteins with disulfide bonds / antibodies, protein complexes, soluble proteins, enzymes, modified proteins, antigens, insoluble proteins, high molecular weight proteins, other proteins, unspecified proteins and oligonucleotides), scale of operation (lab scale / pre-clinical, clinical and commercial) and type of industry served (pharmaceutical and biotechnology, academics, diagnostics, chemicals and food).
  • A detailed assessment of the current market landscape of cell free expression kits, based on several relevant parameters, such as type of cell free system (crude cell lysate-based systems and reconstituted systems), type of host organism (microbial cell free expression system, plant-based cell free expression system, mammalian cell free expression system and insect-based cell free expression system), type of expression method (coupled transcription and translation method and translation method), type of product(s) synthesized (toxic proteins, soluble proteins, membrane proteins, labeled proteins, functionally active proteins, proteins with disulfide bonds, proteins with unnatural amino acids, high molecular weight proteins, insoluble proteins, heat-sensitive proteins, enzymes, other proteins, unspecified proteins, oligonucleotides and whole cells), type of template(s) used (circular DNA, linear DNA, RNA and others), type of compatible promoter(s) (T7, SP6 and others), type of reaction format (batch format, bilayer format, CECF format, and batch and CECF format), yield of positive control (1-5 µg/mL, >5-100 µg/mL, >100-200 µg/mL, >200-500 µg/mL, >500-1,000 µg/mL, >1,000-2,000 µg/mL, >2,000-3,000 µg/mL and >3,000 µg/mL), reaction volume (1-5 µL, >5-100 µL, >100-200 µL, >200-500 µL, >500-1,000 µL, >1,000-2,000 µL, >2,000-3,000 µL, >3,000-10,000 µL and >10,000 µL), reaction temperature (20°C-25°C, >25°C-30°C, >30°C-35°C and >35°C-40°C),  incubation time (1-2 hours, >2-10  hours, >10-20  hours and >20  hours), number of reactions per kit (1-5 reactions / kit, >5-20 reactions / kit, >20-50 reactions / kit, >50-80 reactions / kit and >80-100 reactions / kit), price per kit (USD 150-200, USD >200-500, USD >500-1,000, USD >1,000-2,000, USD >2,000-3,000, USD >3,000-4,000, USD >4,000-5,000 and USD >5,000). In addition, it provides details on cell free expression kits developers, along with analyses based on their year of establishment, company size (in terms of employee count), location of headquarters and leading players (in terms of number of kits provided).
  • A comprehensive company competitiveness analysis of cell free expression service providers based on supplier power (in terms of number of years of experience) and service strength (in terms of type of host organism, service(s) offered, number of product(s) synthesized, industries served and scale of operation).
  • A product competitiveness analysis of cell free expression kits based on various relevant parameters, namely developer power (in terms of number of years of experience) and product competitiveness (in terms of type of cell free system, type of expression method, type of host organism, number of product(s) synthesized, number of template(s) used, number of compatible promoter(s), yield of positive control (µg/ml), reaction volume (µl), incubation time (hours), type of reaction format, reaction temperature and number of reactions per kit).
  • Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) offering cell free expression services. Each profile features a brief overview of the company, details on its cell free expression service portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent players engaged in development of cell free expression kits (shortlisted based on a proprietary criterion), featuring a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.
  • A detailed analysis of recent partnerships inked between stakeholders engaged in this industry, since 2018, covering product development agreements, research and development agreements, technology licensing agreements, acquisitions, product licensing agreements, service alliances, asset acquisitions, joint ventures, product development and commercialization agreements, technology utilization agreements and other relevant agreements. 
  • An analysis of the funding and investments made in the market, since 2018, including seed financing, venture capital financing, capital raised from IPOs, secondary offerings, grants / awards, private placements, other equity and debt financing, at various stages of development in companies that are engaged in this field, based on several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
  • An in-depth analysis of various patents that have been filed / granted related to cell free system since 2015, taking into consideration several relevant parameters, such as patent publication year, type of patent, patent jurisdiction, CPC symbols, type of applicant, emerging focus areas, leading players (in terms of number of patents filled / granted) and leading individual assignees. It also features a detailed patent benchmarking analysis and an insightful valuation analysis, highlighting leading patents (in terms of number of citations).

One of the key objectives of this market report was to estimate the current market size and future growth potential of cell free expression over the forecast period. We have provided an informed estimate on the evolution of the market for the forecast period 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of cell free systems (crude cell lysate-based systems and reconstituted systems), type of host organism (microbial cell free expression system, mammalian cell free expression system, plant-based cell free expression system and other cell free expression systems), type of expression methods (coupled transcription and translation method and translation method), end-users (pharmaceutical and biotechnology companies, academic and research institutes and other end-users), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Takashi Ebihara (Chief Operational Officer, GeneFrontier) 
  • Remberto Martis (Chief Executive Officer and Founder, LenioBio)
  • Bruno Tillier (Chief Executive Officer and Co-founder, Synthelis)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is a cell free system?

Answer: Cell free system is an ¬in-vitro platform which allows the occurrence of biochemical reactions in the absence of living cells.

Question 2: How does cell-free protein synthesis work?

Answer: Cell free systems employ the bio machinery harvested from the lysate of disrupted cells for the manufacturing of a wide array of macromolecular products, mainly proteins.

Question 3: What is the likely growth rate (CAGR) of cell free expression market?

Answer: The cell free expression market is expected to grow at a CAGR of 7.5% during the forecast period.

Question 4: Who are the leading companies offering cell free expression services?

Answer: Examples of key companies currently offering cell free expression services include BioLinker, CusaBio, LenioBio and Touchlight.

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cell Free Systems
3.3. Overview of Cell Free Biomanufacturing
3.3.1. Advantages
3.3.2. Challenges
3.4. Applications of Cell Free Biomanufacturing
3.4.1. Applications in Healthcare Domain
3.4.2. Applications in Other Domains
3.5. Future Perspectives

4. MARKET LANDSCAPE: CELL FREE EXPRESSION SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Cell Free Expression Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Cell Free Expression Service(s) Offered
4.2.5. Analysis by Type of Associated Service(s) Offered
4.2.6. Analysis by Type of Host Organism
4.2.7. Analysis by Type of Product(s) Synthesized
4.2.8. Analysis by Scale of Operation
4.2.9. Analysis by Type of Industry Served

5. MARKET LANDSCAPE: CELL FREE EXPRESSION KITS
5.1. Chapter Overview
5.2. Cell Free Expression Kits: Overall Market Landscape
5.2.1. Analysis by Type of Cell Free System
5.2.2. Analysis by Type of Host Organism
5.2.3. Analysis by Type of Expression Method
5.2.4. Analysis by Type of Product(s) Synthesized
5.2.5. Analysis by Type of Template(s) Used
5.2.6. Analysis by Type of Compatible Promoter(s)
5.2.7. Analysis by Type of Reaction Format
5.2.8. Analysis by Yield of Positive Control
5.2.9. Analysis by Reaction Volume
5.2.10. Analysis by Reaction Temperature
5.2.11. Analysis by Incubation Time
5.2.12. Analysis by Number of Reactions per Kit
5.2.13. Analysis by Kit Price

5.3. Cell Free Expression Kit Providers Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Most Active Players: Analysis by Number of Cell free Expression Kits Developed

6. CELL FREE EXPRESSION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: Cell Free Expression Service Providers
6.4.1. Company Competitiveness Analysis: Small Service Providers
6.4.2. Company Competitiveness Analysis: Mid-sized Service Providers
6.4.3. Company Competitiveness Analysis: Large and Very Service Providers

7. CELL FREE EXPRESSION KITS: PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Product Competitiveness Analysis: Cell Free Expression Kits
7.4.1. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in North America
7.4.2. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in Europe
7.4.3. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in Asia-Pacific and Rest of the World

8. COMPANY PROFILES: CELL FREE EXPRESSION SERVICE PROVIDERS
8.1. Chapter Overview
8.2. BioLinker
8.2.1. Company Overview
8.2.2. Cell Free Expression Service Portfolio
8.2.3. Recent Developments and Future Outlook

8.3. CUSABIO
8.3.1. Company Overview
8.3.2. Cell Free Expression Service Portfolio
8.3.3. Recent Developments and Future Outlook

8.4. LenioBio
8.4.1. Company Overview
8.4.2. Cell Free Expression Service Portfolio
8.4.3. Recent Developments and Future Outlook

8.5. Touchlight
8.5.1. Company Overview
8.5.2. Cell Free Expression Service Portfolio
8.5.3. Recent Developments and Future Outlook

9. COMPANY PROFILES: CELL FREE EXPRESSION KIT PROVIDERS
9.1. Chapter Overview
9.2. biotechrabbit
9.2.1. Company Overview
9.2.2. Cell Free Expression Kit Portfolio
9.2.3 Recent Developments and Future Outlook

9.3. CellFree Sciences
9.3.1. Company Overview
9.3.2. Cell Free Expression Kit Portfolio
9.3.3 Recent Developments and Future Outlook

9.4. Creative Biolabs
9.4.1. Company Overview
9.4.2. Cell Free Expression Kit Portfolio
9.4.3 Recent Developments and Future Outlook

9.5. Diacel Arbor Biosciences
9.5.1. Company Overview
9.5.2. Cell Free Expression Kit Portfolio
9.5.3 Recent Developments and Future Outlook

9.6. Promega
9.6.1. Company Overview
9.6.2. Cell Free Expression Kit Portfolio
9.6.3 Recent Developments and Future Outlook

9.7. Thermo Fisher Scientific
9.7.1. Company Overview
9.7.2. Cell Free Expression Kit Portfolio
9.7.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell free System: Partnerships and Collaborations
10.3.1 Analysis by Year of Partnership 
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Focus Area
10.3.5. Analysis by Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Local and International Agreements
10.3.8. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Cell free System: Funding and Investment Analysis
11.3.1. Analysis of Instances by Year of Investment
11.3.2. Analysis of Amount Invested by Year of Investment
11.3.3. Analysis of Instances by Type of Funding
11.3.4. Analysis of Amount Invested by Type of Funding
11.3.5. Analysis by Instances of Type of Investor
11.3.6. Most Active Players: Analysis by Number of Instances
11.3.7. Most Active Players: Analysis by Amount Invested
11.3.8. Analysis of Amount Invested by Geography
11.3.8.1. Analysis by Region
11.3.8.2. Analysis by Country

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Cell free System: Patent Analysis
12.3.1. Analysis by Patent Publication Year
12.3.2. Analysis by Patent Application Year
12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Type of Applicant
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
12.3.9. Leading Individual Assignees: Analysis by Number of Patents

12.4. Cell free System: Patent Benchmarking Analysis
12.4.1. Analysis by Patent Characteristics
12.5. Cell free System: Patent Valuation
12.6. Leading Patents: Analysis by Number of Citations

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Cell Free Expression Market, 2023-2035
13.3.1. Cell Free Expression Market: Distribution by Type of Cell Free System, 2023 and 2035
13.3.1.1. Cell Free Expression Market for Crude Cell Lysate-based Systems, 2023-2035
13.3.1.2. Cell Free Expression Market for Reconstituted Systems, 2023-2035

13.3.2. Cell Free Expression Market: Distribution by Type of Host Organism, 2023 and 2035
13.3.2.1. Cell Free Expression Market for Microbial Cell Free Expression Systems, 2023-2035
13.3.2.2. Cell Free Expression Market for Mammalian Cell Free Expression Systems, 2023-2035
13.3.2.3. Cell Free Expression Market for Plant-based Cell Free Expression Systems, 2023-2035
13.3.2.4. Cell Free Expression Market for Other Cell Free Expression Systems, 2023-2035

13.3.3. Cell Free Expression Market: Distribution by Type of Expression Method, 2023 and 2035
13.3.3.1. Cell Free Expression Market for Coupled Transcription and Translation Method, 2023-2035
13.3.3.2. Cell Free Expression Market for Translation Method, 2023-2035

13.3.4. Cell Free Expression Market: Distribution by End-User, 2023 and 2035
13.3.4.1. Cell Free Expression Market for Pharmaceutical and Biotechnology Companies, 2023-2035
13.3.4.2. Cell Free Expression Market for Academic and Research Institutes, 2023-2035
13.3.4.3. Cell Free Expression Market for Other End-Users, 2023-2035

13.3.5. Cell Free Expression Market: Distribution by Key Geographical Regions, 2023 and 2035
13.3.5.1. Cell Free Expression Market in North America, 2023-2035
13.3.5.2. Cell Free Expression Market in Europe, 2023-2035
13.3.5.3. Cell Free Expression Market in Asia-Pacific, 2023-2035
13.3.5.4. Cell Free Expression Market in Rest of the World, 2023-2035

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Gene Frontier
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Takashi Ebihara, Chief Operational Officer

14.3. LenioBio
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Remberto Martis, Founder and Chief Executive Officer

14.4. Synthelis
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Bruno Tillier, Co-founder and Chief Executive Officer

15. CONCLUDING REMARKS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape of Cell free Expression Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of Cell free Expression Kits
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Components of Cell free Reaction
Figure 3.2 Applications of Cell free Biomanufacturing
Figure 4.1 Cell free Expression Service Providers: Distribution by Year of Establishment
Figure 4.2 Cell free Expression Service Providers: Distribution by Company Size
Figure 4.3 Cell free Expression Service Providers: Distribution by Location of Headquarters
Figure 4.4 Cell free Expression Service Providers: Distribution by Type of Cell free Biomanufacturing Service(s) Offered
Figure 4.5 Cell free Expression Service Providers: Distribution by Type of Associated Service(s) Offered
Figure 4.6 Cell free Expression Service Providers: Distribution by Type of Host Organism
Figure 4.7 Cell free Expression Service Providers: Distribution by Type of Product(s) Synthesized
Figure 4.8 Cell free Expression Service Providers: Distribution by Scale of Operation
Figure 4.9 Cell free Expression Service Providers: Distribution by Type of Industry Served
Figure 5.1 Cell free Expression Kits: Distribution by Type of Cell free System
Figure 5.2 Cell free Expression Kits: Distribution by Type of Host Organism
Figure 5.3 Cell free Expression Kits: Distribution by Type of Expression Method
Figure 5.4 Cell free Expression Kits: Distribution by Type of Product(s) Synthesized
Figure 5.5 Cell free Expression Kits: Distribution by Type of Template(s) Used
Figure 5.6 Cell free Expression Kits: Distribution by Type of Compatible Promoter(s)
Figure 5.7 Cell free Expression Kits: Distribution by Type of Reaction Format
Figure 5.8 Cell free Expression Kits: Distribution by Yield of Positive Control
Figure 5.9 Cell free Expression Kits: Distribution by Reaction Volume
Figure 5.10 Cell free Expression Kits: Distribution by Reaction Temperature
Figure 5.11 Cell free Expression Kits: Distribution by Incubation Time
Figure 5.12 Cell free Expression Kits: Distribution by Number of Reactions per Kit
Figure 5.13 Cell free Expression Kits: Distribution by Kit Price
Figure 5.14 Cell free Expression Kit Providers: Distribution by Year of Establishment
Figure 5.15 Cell free Expression Kit Providers: Distribution by Company Size
Figure 5.16 Cell free Expression Kit Providers: Distribution by Location of Headquarters
Figure 5.17 Most Active Players: Distribution by Number of Cell free Expression Kits Developed
Figure 6.1 Company Competitiveness Analysis: Small Service Providers
Figure 6.2 Company Competitiveness Analysis: Leading Small Service Providers
Figure 6.3 Company Competitiveness Analysis: Mid-sized Service Providers
Figure 6.4 Company Competitiveness Analysis: Large and Very Large Service Providers
Figure 7.1 Product Competitiveness Analysis: Cell free Expression Kits Developed by Players based in North America
Figure 7.2 Product Competitiveness Analysis: Popular Cell free Expression Kits Developed by Players based in North America
Figure 7.3 Product Competitiveness Analysis: Cell free Expression Kits Developed by Players based in Europe
Figure 7.4 Product Competitiveness Analysis: Popular Cell free Expression Kits Developed by Players based in Europe
Figure 7.5 Product Competitiveness Analysis: Cell free Expression Kits Developed by Players based in Asia Pacific and Rest of the World
Figure 7.6 Product Competitiveness Analysis: Popular Cell free Expression Kits Developed by Players based in Asia Pacific and Rest of the World
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.6 Most Active Players: Distribution by Number of Partnerships
Figure 10.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.8 Partnerships and Collaborations: Local and International Agreements
Figure 11.1 Funding and Investment Analysis: Cumulative Distribution of Number of Instances by Year, 2018-2023
Figure 11.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, 2018-2023 (USD Million)
Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 11.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 11.5 Funding and Investment Analysis: Distribution of Instances by Type of Investor
Figure 11.6 Most Active Players: Distribution by Number of Instances
Figure 11.7 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 11.8 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
Figure 11.9 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Distribution by Patent Publication Year, 2015-2023
Figure 12.3 Patent Analysis: Distribution by Patent Application Year, 2015-2023
Figure 12.4 Patent Analysis: Distribution of Granted Patents and Patent Applications by Publication Year, 2015-2023
Figure 12.5 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Figure 12.6 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Figure 12.7 Patent Analysis: Distribution by CPC Symbols
Figure 12.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 12.9 Leading Industry Players: Distribution by Number of Patents
Figure 12.1 Leading Non-Industry Players: Distribution by Number of Patents
Figure 12.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 12.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 12.13 Patent Analysis: Distribution by Patent Age
Figure 12.14 Cell free System: Patent Valuation
Figure 13.1 Global Cell free Expression Market, 2023-2035 (USD Million)
Figure 13.2 Cell free Expression Market: Distribution by Type of Cell free System, 2023 and 2035
Figure 13.3 Cell free Expression Market for Crude Cell Lysate-based Systems, 2023-2035 (USD Million)
Figure 13.4 Cell free Expression Market for Reconstituted Systems, 2023-2035 (USD Million)
Figure 13.5 Cell free Expression Market: Distribution by Type of Host Organism, 2023 and 2035
Figure 13.6 Cell free Expression Market for Microbial Cell free Expression Systems, 2023-2035 (USD Million)
Figure 13.7 Cell free Expression Market for Mammalian Cell free Expression Systems, 2023-2035 (USD Million)
Figure 13.8 Cell free Expression Market for Plant-based Cell free Expression Systems, 2023-2035 (USD Million)
Figure 13.9 Cell free Expression Market for Other Cell free Expression Systems, 2023-2035 (USD Million)
Figure 13.10 Cell free Expression Market: Distribution by Type of Expression Method, 2023 and 2035
Figure 13.11 Cell free Expression Market for Coupled Transcription and Translation Method, 2023-2035 (USD Million)
Figure 13.12 Cell free Expression Market for Translation Method, 2023-2035 (USD Million)
Figure 13.13 Cell free Expression Market: Distribution by End-User, 2023 and 2035
Figure 13.14 Cell free Expression Market for Pharmaceutical and Biotechnology Companies, 2023-2035 (USD Million)
Figure 13.15 Cell free Expression Market for Academic and Research Institutes, 2023-2035 (USD Million)
Figure 13.16 Cell free Expression Market for Other End-Users, 2023-2035 (USD Million)
Figure 13.17 Cell free Expression Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 13.18 Cell free Expression Market in North America, 2023-2035 (USD Million)
Figure 13.19 Cell free Expression Market in Europe, 2023-2035 (USD Million)
Figure 13.20 Cell free Expression Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 13.21 Cell free Expression Market in Rest of the World, 2023-2035 (USD Million)
Figure 15.1 Concluding Remarks: Cell free Expression Service Providers Market Landscape
Figure 15.2 Concluding Remarks: Cell free Expression Kits Market Landscape
Figure 15.3 Concluding Remarks: Partnerships and Collaborations
Figure 15.4 Concluding Remarks: Funding and Investment Analysis
Figure 15.5 Concluding Remarks: Patent Analysis
Figure 15.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 4.1 Cell free Expression Service Providers: Information on Year of Establishment, Company Size, Location of Headquarters, Type of Host Organism, Type of Cell free Expression Service(s) Offered, and Type of Associated Service(s) Offered
Table 4.2 Cell free Expression Service Providers: Information on Type of Product(s) Synthesized, Scale of Operation and Type of Industry Served
Table 5.1 Cell free Expression Kits: Information on Type of Cell free System, Type of Host Organism, Type of Expression Method, and Type of Product(s) Synthesized
Table 5.2 Cell free Expression Kits: Information on Type of Template(s) Used, Type of Compatible Promoter(s), Type of Reaction Format, Yield of Positive Control, Reaction Volume, Reaction Temperature, Incubation Time, Number of Reactions per Kit and Kit Price
Table 5.3 Cell free Expression Kit Providers: Information on Year of Establishment, Location of Headquarters, Company Size and Type of Organization
Table 8.1 Leading Cell free Expression Service Providers
Table 8.2 BioLinker: Company Overview
Table 8.3 BioLinker: Cell free Expression Service Portfolio
Table 8.4 CUSABIO: Company Overview
Table 8.5 CUSABIO: Cell free Expression Service Portfolio
Table 8.6 LenioBio: Company Overview
Table 8.7 LenioBio: Cell free Expression Service Portfolio
Table 8.8 LenioBio: Recent Developments and Future Outlook
Table 8.9 Touchlight: Company Overview
Table 8.10 Touchlight: Cell free Expression Service Portfolio
Table 8.11 Touchlight: Recent Developments and Future Outlook
Table 9.1 Leading Cell free Expression Kit Providers
Table 9.2 biotechrabbit: Company Overview
Table 9.3 biotechrabbit: Cell free Expression Kit Portfolio
Table 9.4 CellFree Sciences: Company Overview
Table 9.5 CellFree Sciences: Cell free Expression Kit Portfolio
Table 9.6 Creative Biolabs: Company Overview
Table 9.7 Creative Biolabs: Cell free Expression Kit Portfolio
Table 9.8 Daicel Arbor Biosciences: Company Overview
Table 9.9 Daicel Arbor Biosciences: Cell free Expression Kit Portfolio
Table 9.10 Promega: Company Overview
Table 9.11 Promega: Cell free Expression Kit Portfolio
Table 9.12 Thermo Fisher Scientific: Company Overview
Table 9.13 Thermo Fisher Scientific: Cell free Expression Kit Portfolio
Table 9.14 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 10.1 Cell free System: List of Partnerships and Collaborations, 2018-2023
Table 11.1 Cell free System: List of Funding and Investments, 2018-2023
Table 12.1 Patent Analysis: Top CPC Symbols
Table 12.2 Patent Analysis: Top CPC Codes
Table 12.3 Patent Analysis: Summary of Benchmarking Analysis
Table 12.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 12.6 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 14.1 Gene Frontier: Company Snapshot
Table 14.2 LenioBio: Company Snapshot
Table 14.3 Synthelis: Company Snapshot
Table 16.1 Cell free Expression Service Providers: Distribution by Year of Establishment
Table 16.2 Cell free Expression Service Providers: Distribution by Company Size
Table 16.3 Cell free Expression Service Providers: Distribution by Location of Headquarters
Table 16.4 Cell free Expression Service Providers: Distribution by Type of Cell free Expression Service(s) Offered
Table 16.5 Cell free Expression Service Providers: Distribution by Type of Associated Service(s) Offered
Table 16.6 Cell free Expression Service Providers: Distribution by Type of Host Organism
Table 16.7 Cell free Expression Service Providers: Distribution by Type of Product(s) Synthesized
Table 16.8 Cell free Expression Service Providers: Distribution by Scale of Operation
Table 16.9 Cell free Expression Service Providers: Distribution by Type of Industry Served
Table 16.10 Cell free Expression Kits: Distribution by Type of Cell free System
Table 16.11 Cell free Expression Kits: Distribution by Type of Host Organism
Table 16.12 Cell free Expression Kits: Distribution by Type of Expression Method
Table 16.13 Cell free Expression Kits: Distribution by Type of Product(s) Synthesized
Table 16.14 Cell free Expression Kits: Distribution by Type of Template(s) Used
Table 16.15 Cell free Expression Kits: Distribution by Type of Compatible Promoter(s)
Table 16.16 Cell free Expression Kits: Distribution by Type of Reaction Format
Table 16.17 Cell free Expression Kits: Distribution by Yield of Positive Control
Table 16.18 Cell free Expression Kits: Distribution by Reaction Volume
Table 16.19 Cell free Expression Kits: Distribution by Reaction Temperature
Table 16.20 Cell free Expression Kits: Distribution by Incubation Time
Table 16.21 Cell free Expression Kits: Distribution by Number of Reactions per Kit
Table 16.22 Cell free Expression Kits: Distribution by Kit Price
Table 16.23 Cell free Expression Kit Providers: Distribution by Year of Establishment
Table 16.24 Cell free Expression Kit Providers: Distribution by Company Size
Table 16.25 Cell free Expression Kit Providers: Distribution by Location of Headquarters
Table 16.26 Most Active Players: Distribution by Number of Cell free Expression Kits Developed
Table 16.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 16.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.30 Partnerships and Collaborations: Distribution by Focus Area
Table 16.31 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.32 Most Active Players: Distribution by Number of Partnerships
Table 16.33 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.34 Partnerships and Collaborations: Local and International Agreements
Table 16.35 Funding and Investment Analysis: Cumulative Distribution of Number of Instances by Year, 2018-2023
Table 16.36 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, 2018-2023 (USD Million)
Table 16.37 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 16.38 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 16.39 Funding and Investment Analysis: Distribution of Instances by Type of Investor
Table 16.40 Most Active Players: Distribution by Number of Instances
Table 16.41 Most Active Players: Distribution by Amount Invested (USD Million)
Table 16.42 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
Table 16.43 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
Table 16.44 Patent Analysis: Distribution by Type of Patent
Table 16.45 Patent Analysis: Distribution by Patent Publication Year, 2015-2023
Table 16.46 Patent Analysis: Distribution by Patent Application Year, 2015-2023
Table 16.47 Patent Analysis: Distribution of Granted Patents and Patent Applications by Publication Year, 2015-2023
Table 16.48 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Table 16.49 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Table 16.50 Patent Analysis: Distribution by CPC Symbols
Table 16.51 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.52 Leading Industry Players: Distribution by Number of Patents
Table 16.53 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.54 Leading Individual Assignees: Distribution by Number of Patents
Table 16.55 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Table 16.56 Patent Analysis: Distribution by Patent Age
Table 16.57 Cell free System: Patent Valuation
Table 16.58 Global Cell free Expression Market: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.59 Cell free Expression Market: Distribution by Type of Cell free System, 2023 and 2035
Table 16.60 Cell free Expression Market for Crude Cell Lysate-based Systems: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.61 Cell free Expression Market for Reconstituted Systems: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.62 Cell free Expression Market: Distribution by Type of Host Organism, 2023 and 2035
Table 16.63 Cell free Expression Market for Microbial Cell free Expression Systems: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.64 Cell free Expression Market for Mammalian Cell free Expression Systems: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.65 Cell free Expression Market for Plant-based Cell free Expression Systems: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.66 Cell free Expression Market for Other Cell free Expression Systems: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.67 Cell free Expression Market: Distribution by Type of Expression Method, 2023 and 2035
Table 16.68 Cell free Expression Market for Coupled Transcription and Translation Method: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.69 Cell free Expression Market for Translation Method: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.70 Cell free Expression Market: Distribution by End-User, 2023 and 2035
Table 16.71 Cell free Expression Market for Pharmaceutical and Biotechnology Companies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.72 Cell free Expression Market for Academic and Research Institutes: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.73 Cell free Expression Market for Other End-Users: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.74 Cell free Expression Market: Distribution by Key Geographical Regions, 2023 and 2035
Table 16.75 Cell free Expression Market in North America: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.76 Cell free Expression Market in Europe: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.77 Cell free Expression Market in Asia-Pacific: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.78 Cell free Expression Market in Rest of the World: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. Abnova
  2. AMSBIO
  3. ArchiMed
  4. AskBio
  5. Astellas Pharma
  6. Avalon GloboCare
  7. Avantor
  8. Bayer
  9. BigHat Biosciences
  10. BioComber
  11. BioLinker
  12. Bioneer
  13. BioNova Pharmaceuticals
  14. biotechrabbit
  15. Brigham Young University
  16. Cambridge Bioscience
  17. Cancer Research UK
  18. CD Biosynsis
  19. CellFree Sciences
  20. Cornell University
  21. CortecNet
  22. Corteva Agriscience
  23. Creative Biogene
  24. Creative Biolabs
  25. Creative BioMart
  26. Creative Biostructure
  27. Creative Diagnostics
  28. CSO (Costruzione Strumenti Oftalmici)
  29. Cube Biotech
  30. CUSABIO
  31. Daicel Arbor Biosciences
  32. Debut Biotech
  33. E Ink
  34. EpiVax
  35. Epynext Therapeutics
  36. Excellgen
  37. Fraunhofer GES Forschung
  38. Fraunhofer Institute for Cell Therapy and Immunology, Department of Bioanalytics and Bioprocesses (IZI-BB)
  39. Fraunhofer Institute for Molecular Biology and Applied Ecology IME
  40. Frugi Biotechnology
  41. GeneCopoeia
  42. GeneFrontier
  43. General Biosystems
  44. Generation Bio
  45. Genosphere Biotechnologies
  46. GenScript
  47. Germains Seed Technology
  48. Ginkgo Bioworks
  49. GMExpression
  50. GreenLight Biosciences
  51. IAVI
  52. iBody
  53. Imperial College London
  54. Insempra
  55. Instruct-ERIC
  56. Integrated Structural Biology Grenoble
  57. Janssen Biotech
  58. Jena Bioscience
  59. KangMa Healthcode
  60. KanPro Research
  61. Kishida Chemical
  62. LanzaTech
  63. LenioBio
  64. Liberum Biotech
  65. Lifeasible
  66. Lonza
  67. Merck
  68. Moderna
  69. National Institutes of Health (NIH)
  70. National Resilience
  71. Nature's Toolbox (NTx)
  72. New England Biolabs
  73. NMR-Bio
  74. Northwestern University
  75. Nuclera
  76. NUProtein
  77. Odimma Therapeutics
  78. OpenPlant
  79. OriCiro Genomics
  80. PEACCEL
  81. Pfizer
  82. Profacgen
  83. Progeneer
  84. Promega
  85. ProteinExpress
  86. Queensland University of Technology
  87. RD-BIOTECH
  88. Riken
  89. RiNova
  90. Samsung BioLogics
  91. Serum Institute of India
  92. Sigma-Aldrich (aquired by Merck)
  93. Silk Renaissance
  94. Stemloop
  95. Stonehaven Incubate
  96. Sutro Biopharma
  97. SwiftScale Biologics (aquired by National Resilience)
  98. Synthelis
  99. Takara Bio
  100. Tasly Biopharmaceuticals
  101. The Australian National University
  102. The Leukemia & Lymphoma Society
  103. The University of Notre Dame 
  104. The University of Queensland
  105. The University of Tokyo
  106. Thermo Fisher Scientific
  107. Tierra Biosciences
  108. Tokyo Institute of Technology
  109. Touchlight
  110. Trans Chromosomics
  111. UNAPera
  112. University of Gothenberg
  113. University of Natural Resources and Life Sciences (BOKU)
  114. University of Southampton
  115. US Army
  116. Vanderbilt University
  117. Vaxcyte
  118. Vectorial Synthesis Technologies
  119. Versameb
  120. Voyager Therapeutics
  121. Yale University
  122. Zymtronix

Source 1: https://www.sciencedirect.com/science/article/abs/pii/S095816692030197X#
Source 2: https://www.knowledgeridge.com/c/ExpertsViewsDetails/654

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com